generic glp-1 agonist Diabetes patients now have access to first medication: ‘More accessible and affordable’ GLP-1 Agonists For Obesity In

Suppose you are struggling with weight loss or have concerns related to obesity or its associated health risks

Objective To compare weight loss and ongoing costs associated with MBS and GLP-1 RAs in the US

Despite concerns over affordability and side effects, in May, analysts at Morgan Stanley Research predicted the global obesity drug market could peak at $150 in 2035, up from the firms previous forecast of $105 billion

Changes in IC025 values for each GLP-1 RA after gradual expansion of case number

Using propensity matching, the researchers compared 2,894 patients taking a GLP-1 receptor agonist at baseline with 2,894 patients not taking one at baseline

Cai Y, Wei L, Ma L, et al